We were thrilled to eventually attend the 3rd European Conference on GLUT1 Deficiency, which took place virtually. After eagerly awaiting this event throughout the early months of the pandemic in 2020, we are delighted to see it finally come to fruition. This online conference was a success, just like the previous two editions.

We had the opportunity to welcome discussions on our booth about METAglut1™, our innovative IVD blood test, designed to aid the early detection of GLUT1DS.

Glut1 Deficiency Syndrom (Glut1DS), also known as De Vivo Disease, is a rare neuro metabolic disorder that can significantly impact the lives of affected children.

We believe that our diagnostic tool represents a significant advancement in identifying the condition, which can have profound implications for affected individuals and their families.

We were particularly excited to share significant milestones achieved with our partners, AP-HP and CERBA, concerning our validation study for the METAglut1 test.

If you haven’t already, please read our press release: “The METAglut1 test is the result of a collaborative initiative involving METAFORA biosystems, the teams at AP-HP, over 30 clinical trial sites, and Cerba Healthcare. Its goal is to facilitate the early diagnosis of this rare disease, which continues to be underdiagnosed“.